WeBelieve

We CanEnd the HIVEpidemic

Fighting StigmaSaves Lives

in RelentlesslyPursuing aCure for HIV

WeBelieve

We CanEnd the HIVEpidemic

Your browser does not support the video tag.

The Fight Starts Here

Gilead has been a leading innovator for 30 years, working to help people
treat and prevent HIV and to drive research for a cure. Despite
tremendous advances in the field, HIV is still an epidemic with an
unequally heavy impact among the most marginalized populations. Through
our scientific efforts, community support programs and partnerships with
leading health organizations, we’re continuing to break down barriers
and help strengthen public health systems — efforts critical to ending the
HIV epidemic once and for all.

Treatment Can Help People Live Longer and Healthier

People living with HIV who are on treatment and engaged in care can enjoy healthier lives — living longer than ever before thanks in part to our medicines.

Prevention Starts with Education

Comprehensive HIV prevention plays a critical role in ending the epidemic and should include broad community education and biomedical interventions such as PrEP, PEP and TasP.

Our Sights Are Set On a Cure

Finding a cure for HIV presents a formidable challenge. Despite this, we’re relentless in our pursuit because we believe that it may one day be within reach.

11.5M

An estimated 11.5 million people living with HIV in resource-limited countries receive antiretroviral therapies provided by Gilead or one of our manufacturing partners.

Spread Facts, Not Fear

Stigma thrives on ignorance. So when it comes to fighting HIV, it’s
about more than just developing medicines: We need to educate our
communities to improve understanding. It’s all about having and
normalizing the conversation. The Gilead COMPASS (COMmitment to
Partnership in Addressing HIV/AIDS in Southern States) Initiative™ was
established to do just that, helping community-based organizations
reduce HIV-related health disparities, build awareness, advance
education and reduce stigma in the Southern United States.

Your browser does not support the video tag.

Together, We Can Make a Real Impact

Over the 15 years we've worked in resource-limited countries, we've
learned there's no one-size-fits-all approach to treating and preventing
HIV. That's why we partner with nongovernmental organizations,
governments and academic institutions to enhance our collective impact.
Collaborative research not only leads to more innovative approaches,
it also helps countries map their disease burdens. Together, we're able
to raise awareness, reduce stigma and deliver frontline services and
care around the world.

DiscoveryNever Ends

in the Powerof Science

in Findinga Curefor Cancer

WeBelieve

DiscoveryNever Ends

Your browser does not support the video tag.

Cell Therapy Can Change the Game

Chimeric antigen receptor T cell therapy, better known as CAR T, re-engineers a patient’s white blood cells to detect and kill cancer cells. It’s an innovative approach that transforms a patient’s immune system into their own cancer-fighting therapy. We believe it’s a key milestone in the journey to cure cancer, and we’re eager to help advance the field to benefit patients now and in the future.

Your browser does not support the video tag.

Ushering in Our Next Phase of Cancer Therapies

Cell therapy is transforming cancer care with what is potentially the biggest breakthrough since the introduction of combination chemotherapy more than 60 years ago. And it’s advancing quickly, indicating a potential path toward a cure for patients affected by cancer.

Dec 2014

Kite Pharma files first Investigational New Drug (IND) application

APR 2017

Kite wins “Clinical Trial Result of the Year” for CAR T trial in patients with aggressive non-Hodgkin lymphoma (NHL)

Kite, a Gilead Company, becomes first to initiate a global randomized trial for CAR T therapy as a second-line treatment option

JAN 2019

Gilead plans to continue expanding access to our CAR T therapy throughout the U.S. and Europe

Why We’re Investing in Cell Therapy

Kite’s development of its CAR T therapy, which is individually manufactured for each patient, has made a significant difference for treating large B-cell lymphoma. Beyond this, Gilead and Kite are seeking to advance our work by ultimately developing therapies for other hematological cancers and for solid tumors.

Our PeopleMake theDifference

in the Powerof Inclusionand Diversity

CollaborationDrivesInnovation

WeBelieve

Our PeopleMake theDifference

Your browser does not support the video tag.

Diversity Drives Our Innovation

Our diversity defines us. It fuels our work, inspiring us to
innovate, collaborate and ultimately better serve patients around
the world. We embrace diversity in a number of ways at Gilead.
That's where our Employee Resource Groups (ERGs) come in: They help
create a sense of purpose and amplify diverse voices throughout the
company. Built and led by employees, our ERGs provide mentorship
opportunities, boost our collective social awareness and enhance our
community connections.

Gilead Asian Interest Network (GAIN)

GAIN unites Asian employees and their allies to deepen cultural
understanding across the company.

Gilead Leadership Organization of Black Employees (GLOBE)

GLOBE works to cultivate leadership among people of African descent,
advancing opportunities for all people to be valued.

Women at Gilead

Our global network of Women at Gilead boosts how we recruit, develop and support our female employees — so they can thrive now and into the future.

The LGBTQ+ Alliance

The LGBTQ+ Alliance is all about keeping Gilead a place where gender diversity is celebrated, community is prioritized and all people feel empowered.

Gileados

Gileados members embrace and espouse an appreciation for the multifaceted Latino culture at Gilead, with the goal of enhancing the recruitment and retention of diverse talent.

Gilead Veterans Engagement Team (GVET)

GVET plays an important role in how we recognize, appreciate and support veterans, active duty military and their families.

We Stand Up for Our People

The diseases we treat — such as HIV and hepatitis — still
disproportionately affect people who identify as LBGTQ+, and we fiercely
support that community. We advocate for transgender rights. We march in
Pride parades. We host honest conversations about what it means to make
sure everyone feels truly included. We invest in programs that fight
stigma. We stand with our LGBTQ+ employees and take pride in the
difference they make at Gilead and in our communities.